Lithium citrate
Brand names: Li-Liquid, Priadel liquid
Lithium citrate is a lithium salt used as a mood stabiliser in the treatment and prophylaxis of bipolar disorder and recurrent depression, and to control mania.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Its precise mechanism is uncertain, but lithium is thought to modulate neuronal signal transduction, including effects on second-messenger systems, to stabilise mood.
Prescribing in practice
- Lithium has a narrow therapeutic index, and toxicity can be life-threatening, so serum lithium concentrations must be monitored and patients warned about precipitants such as dehydration, infection and interacting drugs.
- Different lithium preparations vary in bioavailability, so the brand should not be changed without re-checking serum levels.
- Renal, thyroid and cardiac function require assessment before and during treatment, as lithium can affect the kidneys and thyroid.
Monitoring
Monitor serum lithium concentrations regularly, together with renal and thyroid function, and review for signs of toxicity such as tremor, vomiting, diarrhoea and confusion.
Counselling the patient
- Maintain a consistent fluid and salt intake and avoid becoming dehydrated.
- Carry a lithium alert card and attend for blood tests as scheduled.
- Seek urgent advice for coarse tremor, persistent vomiting, diarrhoea or drowsiness.
Evidence & guidelines
Lithium is a long-established, evidence-based mood stabiliser recommended by NICE for bipolar disorder, with the MHRA emphasising the need for routine monitoring.
Reference: NICE CG185; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185